Factors associated with Onchocerca volvulus transmission after 20 years of community treatment with ivermectin in savanah and forest areas in Central African Republic: A Cross Sectional Study

中非共和国热带草原和森林地区社区使用伊维菌素治疗20年后,与盘尾丝虫传播相关的因素:一项横断面研究

阅读:2

Abstract

The Central African Republic has endemic onchocerciasis in 20 health districts in savannah and forest areas. The country organised a mass distribution campaign of invermectin in 2023 through the National Onchocerciasis Control Programme. The objectives of this study were to identify factors of persistent Onchocerca volvulus transmission. A cross-sectional study was carried out in Bossangoa (savannah area) and Kémo (forest area) health districts. Using kelsey'formula 1600 respondents were recruited. Dependent variable is onchocerciasis status. Bivariate analysis was carried out to determine the differential risks for onchocerciasis infection, each variable being taken separately. The strength of statistical associations was measured by prevalence rates (PR) from log-binomial regression model and their 95% confidence intervals. Onchocerciasis prevalence is 26.45% in Bossangoa (95% CI = 23.76-29.14), and 14.79% (84/568) in Kémo (95% CI = 23.53-29.37). In both savannah and forest areas, the common factors incriminated in the transmission of onchocerciasis after several years of community distribution of ivermectin were: young age (PR = 2.44 (1.97-3.03), p < 0.001; 3.63 (2.32-5.70), p < 0.001 respectively), not taking ivermectin (PR = 2.31 (1.86-2.87), p < 0.001; 6.84 (4.42-10.57), p < 0.001 respectively), male sex (PR = 2.54 (2.04-3.16), p <0.001; 1.79 (1.19-2.69), p = 0.002 respectively), living near rivers and in rural areas. Despite efforts, the prevalence of onchocerciasis remained high in the 2 districts. The main factors incriminated in the persistence of transmission were failure to take ivermectin, male sex and young age. The National Onchocerciasis Control Programme needs to review its planning of activities, ensuring that the population is constantly made aware before drugs are distributed, and increasing the number of days of community-based distribution in order to improve therapeutic coverage.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。